Drugs / SYHA1805
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04977570 | Jul 2021 → May 2022 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04645901 | Dec 2020 → May 2022 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-05-28 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1805" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-05-28 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1805" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHA1805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04645901 ↗ |
| Route | Oral | “single dose of oral SYHA1805 tablets” NCT04645901 ↗ |